Irina Bronova

Irina Bronova

Auto-generated profile, based on publicly available information

Irina Bronova

Department of Medicine National Jewish Health Denver Colorado USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Allergy
Verified
Journal Article
Open access
EBEvgeny Berdyshev
Evgeny Berdyshev
EGElena Goleva
Elena Goleva
RBRobert Bissonnette
Robert Bissonnette
IBIrina Bronova
Irina Bronova
ABAnna Sofia Bronoff
Anna Sofia Bronoff
DLDonald Y.M. Leung
Donald Y.M. Leung
Background: Atopic dermatitis (AD) is characterized by abnormal skin lipids that are largely driven by hyperactivated type 2 immune responses. The antibody to the α‐subunit of interleukin (IL)‐4 receptor, dupilumab, was recently approved to treat AD and demonstrated strong efficacy. However, the role of dupilumab therapy in the regulation of skin barrier structure and function has not been fully explored.Methods: We have evaluated the content of lipids and transepidermal water loss (TEWL) in lesional and non‐lesional skin of adults and adolescents with moderate‐to‐severe AD over the course of 16‐week treatment with dupilumab and compared those values with that of matched healthy volunteers.Results: Dupilumab treatment provided a significant decrease in TEWL in AD lesions, lowering it almost to the levels seen in the skin of healthy subjects. Blocking IL‐4/IL‐13 signaling with dupilumab normalized lipid composition (decreased levels of ceramides with non‐hydroxy fatty acids and C18‐sphingosine and increased the level of esterified omega‐hydroxy fatty acid‐containing ceramides) and increased ceramide chain length in lesional as well as non‐lesional stratum corneum of AD patients. Partial changes for these parameters were already observed after 2 weeks, with a full response achieved after 8 weeks of dupilumab treatment.Conclusions: Inhibition of IL‐4/IL‐13 signaling by dupilumab allows restoration of skin lipid composition and barrier function in patients with moderate‐to‐severe AD.

19 January 2023 in Allergy
Verified
Journal Article
Open access
JKJihyun Kim
Jihyun Kim
BKByung Eui Kim
Byung Eui Kim
EBEvgeny Berdyshev
Evgeny Berdyshev
IBIrina Bronova
Irina Bronova
LBLianghua Bin
Lianghua Bin
DLDonald Y.M. Leung
Donald Y.M. Leung
Background: Staphylococcus (S) aureus colonization is known to cause skin barrier disruption in atopic dermatitis (AD) patients. However, it has not been studied how S. aureus induces aberrant epidermal lipid composition and skin barrier dysfunction.Methods: Skin tape strips (STS) and swabs were obtained from 24 children with AD (6.0 ± 4.4 years) and 16 healthy children (7.0 ± 4.5 years). Lipidomic analysis of STS samples was performed by mass spectrometry. Skin levels of methicillin‐sensitive and methicillin‐resistant S. aureus (MSSA and MRSA) were evaluated. The effects of MSSA and MRSA were evaluated in primary human keratinocytes (HEKs) and organotypic skin cultures.Results: AD and organotypic skin colonized with MRSA significantly increased the proportion of lipid species with nonhydroxy fatty acid sphingosine ceramide with palmitic acid ([N‐16:0 NS‐CER], sphingomyelins [16:0–18:0 SM]), and lysophosphatidylcholines [16:0–18:0 LPC], but significantly reduced the proportion of corresponding very long‐chain fatty acids (VLCFAs) species (C22–28) compared to the skin without S. aureus colonization. Significantly increased transepidermal water loss (TEWL) was found in MRSA‐colonized AD skin. S. aureus indirectly through interleukin (IL)‐1β, tumor necrosis factor (TNF)‐α, IL‐6, and IL‐33 inhibited expression of fatty acid elongase enzymes (ELOVL3 and ELOVL4) in HEKs. ELOVL inhibition was more pronounced by MRSA and resulted in TEWL increase in organotypic skin.Conclusion: Aberrant skin lipid profiles and barrier dysfunction are associated with S. aureus colonization in AD patients. These effects are attributed to the inhibition of ELOVLs by S. aureus‐induced IL‐1β, TNF‐α, IL‐6, and IL‐33 seen in keratinocyte models and are more prominent in MRSA than MSSA.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
EBEvgeny Berdyshev
Evgeny Berdyshev
JKJihyun Kim
Jihyun Kim
BKByung Eui Kim
Byung Eui Kim
EGElena Goleva
Elena Goleva
TLTaras Lyubchenko
Taras Lyubchenko
DLDonald Y.M. Leung
Donald Y.M. Leung
Background: Atopic dermatitis (AD), or atopic eczema, commonly occurs in children and can progress into severe phenotype or atopic march, causing significant impairment in quality of life. To prevent the development of AD, it is important to find early biomarkers to predict the future onset of AD before any clinical manifestations. Methods: Newborns (n=111) with and without family history of atopic diseases (risk group, n=74 control group, n=37) were enrolled in Seoul, Korea. Skin tape strips (STS) were collected from the volar area of the forearm at the age of 2 months before any signs of clinical AD, and children were clinically monitored until they reached 2 years of age to ensure the presence or absence of AD. STS were subjected to lipidomic analyses by the LC-MS/MS and cytokine determination by Meso Scale Discovery (MSD) U-Plex assay. Findings: Overall, 22/74 (29·7%) and 5/37 (13 5%) infants developed AD in the high risk group and the control group, respectively. In the stratum corneum (SC) of future AD children, protein-bound ceramides were significantly decreased, and unsaturated sphingomyelin species and “short-chain” NS- and AS-ceramides were elevated as compared to healthy children. Thymic stromal lymphopoietin and interleukin 13 levels were increased in the SC of future AD subjects at two months of age (by 74 5% and 78·3%, p=0·0022 and p<0 0001, respectively). Univariable logistic regression analysis revealed strong AD predicting power of the combination of type 2 cytokines and dysregulated lipids, with an odds ratio reaching 51·3. Interpretation: Non-invasive STS analysis at two months of age can identify asymptomatic children at risk of future AD development with a high probability. Trial Registration Details: y. The study protocol was registered in the WHO International Clinical Trials Registry Platform (ICTRP). The registration number is KCT0007979. Funding Information: The study was funded by Edelstein Family Chair of Pediatric Allergy-Immunology at National Jewish Health and by Korea Environment Industry and Technology Institute (KEITI) through Environmental Health Action Program, funded by Korea Ministry of Environment (MOE) (2017001360006). Declaration of Interests: EB reports research grants with LEO Pharma and Sanofi Genzyme. EG reports research grants with Sanofi Genzyme. DYML reports consulting with Boehringer-Ingelheim, Evommune, Genetech, LEO Pharma, and Incyte; reports research grant with Sanofi Genzyme. All other authors have nothing to report. Ethics Approval Statement: This study was approved by the institutional review board at Samsung Medical Center in Seoul (IRB No. 2016-12-111), and written informed consent was obtained from all parents prior to participation in this study.

13 April 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
EBEvgeny Berdyshev
Evgeny Berdyshev
EGElena Goleva
Elena Goleva
KLKatherine Lyubchenko
Katherine Lyubchenko
ABAnna Sofia Bronoff
Anna Sofia Bronoff
IBIrina Bronova
Irina Bronova
DLDonald Y.M. Leung
Donald Y.M. Leung